Zotide, marketed under the brand name Zotide, represents a cutting-edge therapeutic solution for individuals suffering from osteoporosis and related bone disorders. Manufactured by Cipla Limited, each 3 ml injection of Zotide contains 750 mcg of Teriparatide, a synthetic form of parathyroid hormone (PTH) known for its bone-stimulating properties and role in bone metabolism regulation.

Key Features:

1. Bone Remodeling Agent: Zotide contains Teriparatide, a recombinant human PTH analog that stimulates bone formation and enhances bone density. By promoting osteoblast activity and inhibiting osteoclast function, Teriparatide helps restore bone balance, making it an effective treatment for osteoporosis and bone loss.
2. Indicated for Osteoporosis: Zotide is indicated for the treatment of osteoporosis in postmenopausal women and men at high risk of fractures. Its ability to increase bone mineral density and reduce the risk of vertebral and non-vertebral fractures makes it a valuable therapeutic option for individuals with severe osteoporosis.
3. Anabolic Effect on Bone: Teriparatide exerts anabolic effects on bone tissue, stimulating the formation of new bone and enhancing bone strength. This leads to improved bone quality and reduced fracture risk, particularly in patients with severe osteoporosis or those who have experienced previous fractures.
4. Convenient Dosage Form: Zotide is formulated as an injectable solution, allowing for convenient and precise dosing. Each prefilled syringe contains the exact dosage of Teriparatide, eliminating the need for dose adjustments or complex preparation steps.
5. Proven Clinical Efficacy: Clinical studies have demonstrated the efficacy of Zotide in increasing bone mineral density and reducing the incidence of fractures in patients with osteoporosis. Its role in promoting bone formation and improving bone quality has been well-established, making it a preferred choice for osteoporosis management.
6. Well-Tolerated: Zotide is generally well-tolerated, with most adverse effects being mild and transient. Common side effects may include injection site reactions, dizziness, and leg cramps. Serious adverse effects such as hypercalcemia are rare but may occur with prolonged use or high doses of Teriparatide.

Usage Guidelines:

• Zotide should be administered by subcutaneous injection once daily, preferably at the same time each day.
• The recommended dosage of Zotide is 20 mcg (750 mcg in 3 ml) per day, administered for up to 24 months.
• Close monitoring of bone mineral density, calcium levels, and renal function is recommended during Zotide therapy to ensure optimal treatment outcomes and safety.

Zotide (Teriparatide 750 mcg Injection) offers a targeted and effective therapeutic approach to managing osteoporosis and improving bone health. With its bone-stimulating properties, convenient dosage form, and proven clinical efficacy, Zotide stands as a valuable treatment option for individuals seeking to reduce fracture risk and maintain bone strength.